Physician profile
Solomon Krow
NPI 1417219379
$2,670.16
in general payments reported to CMS, 2019-2025
22 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.33 · 2021: $66.43 · 2022: $314 · 2023: $1,387 · 2024: $621 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $490.43 | 2021-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $388.90 | 2022-2024 | Tezspire, Fasenra |
| Inari Medical, INC. | $350.52 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $321.52 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $286.91 | 2023-2024 | Impella |
| Pulmonx Corporation | $130.35 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Regeneron Healthcare Solutions, INC. | $106.23 | 2023-2024 | Dupixent |
| United Therapeutics Corporation | $81.33 | 2019 | |
| Amgen INC. | $79.95 | 2023-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $78.23 | 2021-2024 | |
| Harmony Biosciences LLC | $49.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.96 | 2023 | |
| Electromed, INC. | $38.94 | 2021 | |
| Abbvie INC. | $37.02 | 2022-2024 | |
| Mylan Specialty L.P. | $35.90 | 2022-2023 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.65 | 2024 | Acthar |
| Genzyme Corporation | $29.89 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.13 | 2023 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $17.38 | 2024 | Lumryz |
| La Jolla Pharmaceutical Company | $15.40 | 2024 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $13.65 | 2022 | |
| Dexcom, INC. | $13.37 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomon Krow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.